$TTOO
T2 Biosystems, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019007862 Filed on March 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $1.785M $1.792M $10.50M
YoY Change -22.76% 7.89% 125.03%
Cost Of Revenue $4.390M $5.630M $15.40M
YoY Change 34.13% -10.72% 28.03%
Gross Profit -$2.600M -$3.840M -$4.900M
YoY Change 170.27% -17.33% -33.44%
Gross Profit Margin -145.66% -214.29% -46.67%
Selling, General & Admin $7.055M $6.458M $25.70M
YoY Change 22.59% 16.05% 12.92%
% of Gross Profit
Research & Development $3.901M $3.297M $14.49M
YoY Change -17.32% -20.67% -38.95%
% of Gross Profit
Depreciation & Amortization $600.0K $590.0K $2.449M
YoY Change -4.61% -21.33% -16.7%
% of Gross Profit
Operating Expenses $10.96M $9.755M $40.19M
YoY Change 4.61% 0.35% -13.56%
Operating Profit -$13.56M -$13.59M -$45.09M
YoY Change 18.57% -5.37% -16.27%
Interest Expense -$1.782M -$1.770M -$6.682M
YoY Change 13.65% -54.62% -24.98%
% of Operating Profit
Other Income/Expense, Net $194.0K $220.0K $619.0K
YoY Change 115.56% 214.29% 87.01%
Pretax Income -$15.15M -$15.15M -$51.15M
YoY Change 17.35% -16.71% -18.07%
Income Tax
% Of Pretax Income
Net Earnings -$15.15M -$15.15M -$51.15M
YoY Change 17.3% -16.73% -18.06%
Net Earnings / Revenue -848.57% -845.37% -487.17%
Basic Earnings Per Share
Diluted Earnings Per Share -$342.1K -$343.1K -$1.261M
COMMON SHARES
Basic Shares Outstanding 44.32M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.40M $50.81M $50.81M
YoY Change 25.8% 21.56% 21.56%
Cash & Equivalents $37.40M $50.81M $50.81M
Short-Term Investments
Other Short-Term Assets $1.740M $1.340M $1.340M
YoY Change 176.19% 88.73% 88.73%
Inventory $2.664M $2.677M $2.680M
Prepaid Expenses
Receivables $1.773M $1.786M $1.790M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $43.58M $56.61M $56.61M
YoY Change 31.96% 27.73% 27.73%
LONG-TERM ASSETS
Property, Plant & Equipment $7.128M $7.315M $7.320M
YoY Change -18.16% -26.96% -26.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $206.0K $206.0K $390.0K
YoY Change 0.0% -23.13% -26.42%
Total Long-Term Assets $11.98M $7.701M $7.700M
YoY Change 31.67% -26.96% -26.94%
TOTAL ASSETS
Total Short-Term Assets $43.58M $56.61M $56.61M
Total Long-Term Assets $11.98M $7.701M $7.700M
Total Assets $55.56M $64.31M $64.31M
YoY Change 31.9% 17.22% 17.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $618.0K $744.0K $740.0K
YoY Change -20.67% 14.81% 13.85%
Accrued Expenses $7.784M $6.073M $6.070M
YoY Change 38.85% -2.33% -2.41%
Deferred Revenue $658.0K $697.0K
YoY Change -59.85%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $42.45M $42.37M $42.37M
YoY Change 2.78% 4.1% 4.1%
Total Short-Term Liabilities $53.74M $52.30M $52.30M
YoY Change 5.52% 0.99% 1.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $3.400M $630.0K $630.0K
YoY Change 400.0% -13.7% -13.7%
Total Long-Term Liabilities $3.400M $630.0K $630.0K
YoY Change 163.57% -63.79% -63.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.74M $52.30M $52.30M
Total Long-Term Liabilities $3.400M $630.0K $630.0K
Total Liabilities $57.14M $52.92M $52.92M
YoY Change 9.44% -1.12% -1.12%
SHAREHOLDERS EQUITY
Retained Earnings -$332.3M -$317.2M
YoY Change 19.14% 19.18%
Common Stock $330.7M $328.6M
YoY Change 23.02% 22.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.580M $11.39M $11.39M
YoY Change
Total Liabilities & Shareholders Equity $55.56M $64.31M $64.31M
YoY Change 31.9% 17.22% 17.23%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$15.15M -$15.15M -$51.15M
YoY Change 17.3% -16.73% -18.06%
Depreciation, Depletion And Amortization $600.0K $590.0K $2.449M
YoY Change -4.61% -21.33% -16.7%
Cash From Operating Activities -$12.87M -$9.690M -$40.14M
YoY Change 9.58% -12.55% -15.88%
INVESTING ACTIVITIES
Capital Expenditures $194.0K $360.0K $593.0K
YoY Change 246.43% 200.0% -76.05%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$194.0K $360.0K -$593.0K
YoY Change 246.43% 200.0% -76.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -344.0K -90.00K 49.66M
YoY Change -1.15% -35.71% 168.34%
NET CHANGE
Cash From Operating Activities -12.87M -9.690M -40.14M
Cash From Investing Activities -194.0K 360.0K -593.0K
Cash From Financing Activities -344.0K -90.00K 49.66M
Net Change In Cash -13.41M -9.420M 8.926M
YoY Change 10.37% -15.14% -128.17%
FREE CASH FLOW
Cash From Operating Activities -$12.87M -$9.690M -$40.14M
Capital Expenditures $194.0K $360.0K $593.0K
Free Cash Flow -$13.06M -$10.05M -$40.73M
YoY Change 10.71% -10.27% -18.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 ttoo Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense
TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense
0
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Registrant Name
EntityRegistrantName
T2 Biosystems, Inc.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001492674
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Trading Symbol
TradingSymbol
TTOO
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41799000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1786000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
467000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1340000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
708000
CY2018Q4 us-gaap Inventory Net
InventoryNet
2677000
CY2017Q4 us-gaap Inventory Net
InventoryNet
1344000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
56608000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
44318000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7315000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10015000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
180000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
260000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
206000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
268000
CY2018Q4 us-gaap Assets
Assets
64309000
CY2017Q4 us-gaap Assets
Assets
54861000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
744000
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q2 dei Entity Public Float
EntityPublicFloat
286600000
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44320048
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50805000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
648000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6073000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6218000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2142000
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2238000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
42373000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
697000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1736000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
268000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
246000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52297000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51782000
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
1008000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
492000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
731000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
133000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9897000
CY2017Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2018Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1700000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
2710000
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
564000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1819000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
172000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-62428000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.26
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-54804000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.94
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40558826
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2238000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
120000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-314000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-61000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-279000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
724000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-807000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40138000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47718000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5487000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2476000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5487000
CY2018 ttoo Proceeds From Issuance Initial Public Offering Net Of Offering Costs
ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts
49237000
CY2017 ttoo Proceeds From Issuance Initial Public Offering Net Of Offering Costs
ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts
18640000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73748000
CY2017 ttoo Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense
TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense
0
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
80000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49657000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
82000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
55590000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
58518000
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25697000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-45090000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-53852000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-50878000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4098000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
331000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6682000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8907000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14489000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23733000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22757000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24077000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
54958000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
40696000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1059000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73922000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50985000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
3786000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
3959000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
189000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51755000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31689000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-174000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42059000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4843780
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10500000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24009000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18622000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
9897000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
4790000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
4848000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
2216000
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-112000
CY2018 us-gaap Production Related Impairments Or Charges
ProductionRelatedImpairmentsOrCharges
683000
CY2017 us-gaap Production Related Impairments Or Charges
ProductionRelatedImpairmentsOrCharges
2571000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-26000
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
96000
CY2018 us-gaap Straight Line Rent
StraightLineRent
217000
CY2017 us-gaap Straight Line Rent
StraightLineRent
115000
CY2016 us-gaap Straight Line Rent
StraightLineRent
250000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1319000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
140000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
570000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-125000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-68000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1089000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
110000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
121000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
580000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-709000
CY2016 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
299000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46442000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
593000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2476000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-593000
CY2016 ttoo Proceeds From Issuance Initial Public Offering Net Of Offering Costs
ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts
-385000
CY2018 ttoo Proceeds From Issuance Of Common Stock And Stock Options Exercised
ProceedsFromIssuanceOfCommonStockAndStockOptionsExercised
1967000
CY2017 ttoo Proceeds From Issuance Of Common Stock And Stock Options Exercised
ProceedsFromIssuanceOfCommonStockAndStockOptionsExercised
1059000
CY2016 ttoo Proceeds From Issuance Of Common Stock And Stock Options Exercised
ProceedsFromIssuanceOfCommonStockAndStockOptionsExercised
1018000
CY2016 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
39723000
CY2016 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
43803000
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1547000
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1194000
CY2016 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
32404000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18505000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8926000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
2732000
CY2018 ttoo Transfer Of T2 Owned Instruments And Components To Inventory
TransferOfT2OwnedInstrumentsAndComponentsToInventory
244000
CY2017 ttoo Transfer Of T2 Owned Instruments And Components To Inventory
TransferOfT2OwnedInstrumentsAndComponentsToInventory
431000
CY2017 ttoo Transfer Of Liabilities To Accrued Expenses And Other Current Liabilities
TransferOfLiabilitiesToAccruedExpensesAndOtherCurrentLiabilities
585000
CY2017 ttoo Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
59000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 Biosystems, Inc. (the &#8220;Company&#8221;) was incorporated on April&#160;27, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is an&#160;<font style="font-style:italic;">in vitro</font>&#160;diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company is using its T2 Magnetic Resonance technology (&#8220;T2MR&#8221;) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (&#8220;CFU/mL&#8221;). The Company&#8217;s initial development efforts target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September&#160;22, 2014, the Company received market clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its first two products, the T2Dx Instrument (the &#8220;T2Dx&#8221;) and T2Candida Panel (&#8220;T2Candida&#8221;). On May 24, 2018, the Company received market clearance from the FDA for its T2Bacteria Panel (&#8220;T2Bacteria&#8221;).</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has devoted substantially all of its efforts to research and development, business planning, recruiting management and technical staff, acquiring operating assets, raising capital, and, most recently, the commercialization and improvement of its existing products.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2018, the Company has cash and cash equivalents of $50.8 million and an accumulated deficit of $317.2 million. <font style="color:#000000;">The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (&#8220;PIPE&#8221;) financing, its September 2017 public offering, its June 2018 public offering, private placements of redeemable convertible preferred stock and through debt financing arrangements</font>.&#160;</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other newly commercial life science companies, including, but not limited to commercially launching the Company&#8217;s products, development and market acceptance of the Company&#8217;s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Having obtained authorization from the FDA to market the T2Dx, T2Candida, and T2Bacteria, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company&#8217;s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company&#8217;s business, results of operations, financial condition and the Company&#8217;s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria and other product candidates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Accounting Standards Codification (&#8220;ASC&#8221;) 205-40,&#160;<font style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font>, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes that its existing cash and cash equivalents at December 31, 2018 will be sufficient to allow the Company to fund its current operating plan through March 2020. However, as certain elements of the Company&#8217;s operating plan are outside of the Company&#8217;s control, including the receipt of certain development and regulatory milestone payments under the Company&#8217;s Co-Development agreements, they cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from the Company&#8217;s Co-Development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company&#8217;s control. In addition, the Company is required to maintain a minimum cash balance under its Term Loan Agreement with CRG Servicing LLC (&#8220;CRG&#8221;) (Note 6).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning milestone payments pursuant the Company&#8217;s Co- Development agreements, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date the financial statements are issued.&nbsp;&nbsp;Management has concluded the likelihood that its plan to obtain sufficient funding from one or more of these sources or adequately reduce expenditures will be successful, while reasonably possible, is less than probable.&nbsp;&nbsp;Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19139000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11307000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9124000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options, as well as restricted stock units that have market conditions, deferred tax valuation allowances, revenue recognition, to record expenses relating to research and development contracts, accrued expenses, the fair value of a derivative liability and to classify the value of instrument raw material and work-in-process inventory between inventory and property and equipment. The Company bases its estimates on historical experience and other market<font style="font-family:MS Mincho;">&#8209;</font>specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.</p>
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
328514000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
267421000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317171000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266117000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11387000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1340000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64309000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54861000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44175441
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35948900
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44175441
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35948900
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4666000
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4080000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
619000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-51153000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32131512
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26015751
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
46939000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4848000
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
215000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1018000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39723000
CY2016 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1829000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
39338000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4790000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18581000
CY2018 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
99000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1967000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
49237000
CY2018 us-gaap Profit Loss
ProfitLoss
-51153000
CY2017 us-gaap Profit Loss
ProfitLoss
-62428000
CY2016 us-gaap Profit Loss
ProfitLoss
-54804000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2449000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2940000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2280000
CY2018 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is the officer&#8217;s or director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company&#8217;s leases.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company&#8217;s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2018 and 2017, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</p>
CY2018Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
300000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q4 ttoo Number Of Financial Institutions
NumberOfFinancialInstitutions
1
CY2017Q4 ttoo Number Of Financial Institutions
NumberOfFinancialInstitutions
1
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
639000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
539000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1713000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
562000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
325000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
243000
CY2018Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3700000
CY2018 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation
The Company expects to recognize revenue on the remaining performance obligations over the next 2 years.
CY2018Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
600000
CY2018Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1700000
CY2018Q4 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
500000
CY2018 ttoo Transfer Of Liabilities To Accrued Expenses And Other Current Liabilities
TransferOfLiabilitiesToAccruedExpensesAndOtherCurrentLiabilities
1400000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2940000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2793000
CY2018Q4 ttoo Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
359000
CY2017Q4 ttoo Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
818000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
576000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1018000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2198000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1589000
CY2018Q4 ttoo Long Term Debt Maturities Repayments Of Principal And Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInNextTwelveMonths
47362000
CY2018Q4 ttoo Debt Instrument Carrying Amount Including Interest
DebtInstrumentCarryingAmountIncludingInterest
47362000
CY2018Q4 ttoo Debt Instrument Paid In Kind Interest Relating To Future Payments
DebtInstrumentPaidInKindInterestRelatingToFuturePayments
3170000
CY2018Q4 us-gaap Notes Payable
NotesPayable
42373000
CY2018 ttoo Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3000000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3500000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4900000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9768000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4705000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4730000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5969425
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4920538
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.036
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.025
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.012
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.010
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.015
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.013
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.527
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.250
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.122
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.403
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
73612000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
62670000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
7603000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6924000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3156000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2723000
CY2018Q4 ttoo Deferred Tax Assets Start Up Expenditures
DeferredTaxAssetsStartUpExpenditures
3026000
CY2017Q4 ttoo Deferred Tax Assets Start Up Expenditures
DeferredTaxAssetsStartUpExpenditures
3214000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3130000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2127000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
90527000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
77658000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
90361000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
77546000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
166000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
112000
CY2018Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
166000
CY2017Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
112000
CY2018 ttoo Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
32900000
CY2018 ttoo Tax Cuts And Jobs Act Of2017 Incomplete Accounting Adjustment In Deferred Tax Assets Valuation Allowance
TaxCutsAndJobsActOf2017IncompleteAccountingAdjustmentInDeferredTaxAssetsValuationAllowance
-32900000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12800000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6400000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22100000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2225000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2277000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1926000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6428000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2000000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1900000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1800000
CY2018 ttoo Payment Of License Fees And Reimbursed Patent Costs
PaymentOfLicenseFeesAndReimbursedPatentCosts
0
CY2017 ttoo Payment Of License Fees And Reimbursed Patent Costs
PaymentOfLicenseFeesAndReimbursedPatentCosts
30000
CY2016 ttoo Payment Of License Fees And Reimbursed Patent Costs
PaymentOfLicenseFeesAndReimbursedPatentCosts
31000
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
84678
CY2018 ttoo Royalty On Net Sales Sublicensing Gross Revenue
RoyaltyOnNetSalesSublicensingGrossRevenue
0.10
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
126000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
190000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
237000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2311000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3931000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2466000
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1792000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4718000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3749000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2725000
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3297000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5755000
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7611000
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5873000
CY2018Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6458000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
13746000
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
14818000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
11640000
CY2018Q4 us-gaap Costs And Expenses
CostsAndExpenses
15386000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11435000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10887000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9174000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-13594000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-12913000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-12324000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-10767000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-15149000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
941000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
956000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1108000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1661000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6585000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7112000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5880000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4156000
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5874000
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5759000
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5559000
CY2017Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5565000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
14086000
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
14860000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
13545000
CY2017Q4 us-gaap Costs And Expenses
CostsAndExpenses
16027000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13145000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13904000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12437000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-14366000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-14703000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-15456000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-14076000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-18193000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51

Files In Submission

Name View Source Status
0001564590-19-007862-index-headers.html Edgar Link pending
0001564590-19-007862-index.html Edgar Link pending
0001564590-19-007862.txt Edgar Link pending
0001564590-19-007862-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmpx0w2ns1d0000001.jpg Edgar Link pending
gn404rmebpmn000001.jpg Edgar Link pending
gnljsq2zikh4000001.jpg Edgar Link pending
gnljsq2zikh4000002.jpg Edgar Link pending
gnljsq2zikh4000003.jpg Edgar Link pending
gqgf2j4cuk2c000001.jpg Edgar Link pending
gqgf2j4cuk2c000002.jpg Edgar Link pending
gqgf2j4cuk2c000003.jpg Edgar Link pending
gqgf2j4cuk2c000004.jpg Edgar Link pending
gqgf2j4cuk2c000005.jpg Edgar Link pending
gqgf2j4cuk2c000006.jpg Edgar Link pending
gqgf2j4cuk2c000007.jpg Edgar Link pending
gqgf2j4cuk2c000008.jpg Edgar Link pending
gqgf2j4cuk2c000009.jpg Edgar Link pending
gqgf2j4cuk2c000010.jpg Edgar Link pending
gqgf2j4cuk2c000011.jpg Edgar Link pending
gqgf2j4cuk2c000012.jpg Edgar Link pending
gqgf2j4cuk2c000013.jpg Edgar Link pending
gqgf2j4cuk2c000014.jpg Edgar Link pending
gqgf2j4cuk2c000015.jpg Edgar Link pending
gqgf2j4cuk2c000016.jpg Edgar Link pending
gqgf2j4cuk2c000017.jpg Edgar Link pending
gqgf2j4cuk2c000018.jpg Edgar Link pending
gqgf2j4cuk2c000019.jpg Edgar Link pending
gqgf2j4cuk2c000020.jpg Edgar Link pending
gqgf2j4cuk2c000021.jpg Edgar Link pending
gqgf2j4cuk2c000022.jpg Edgar Link pending
gqgf2j4cuk2c000023.jpg Edgar Link pending
gqgf2j4cuk2c000024.jpg Edgar Link pending
gqgf2j4cuk2c000025.jpg Edgar Link pending
gqgf2j4cuk2c000026.jpg Edgar Link pending
gqgf2j4cuk2c000027.jpg Edgar Link pending
gqgf2j4cuk2c000028.jpg Edgar Link pending
gqgf2j4cuk2c000029.jpg Edgar Link pending
gqgf2j4cuk2c000030.jpg Edgar Link pending
gqgf2j4cuk2c000031.jpg Edgar Link pending
gqgf2j4cuk2c000032.jpg Edgar Link pending
gqgf2j4cuk2c000033.jpg Edgar Link pending
gqgf2j4cuk2c000034.jpg Edgar Link pending
gqgf2j4cuk2c000035.jpg Edgar Link pending
gwtykakudrwg000001.jpg Edgar Link pending
gyclqqfdcji5000001.jpg Edgar Link pending
gyclqqfdcji5000002.jpg Edgar Link pending
gyclqqfdcji5000003.jpg Edgar Link pending
gyclqqfdcji5000004.jpg Edgar Link pending
gyclqqfdcji5000005.jpg Edgar Link pending
gyclqqfdcji5000006.jpg Edgar Link pending
gyclqqfdcji5000007.jpg Edgar Link pending
gyclqqfdcji5000008.jpg Edgar Link pending
gyclqqfdcji5000009.jpg Edgar Link pending
gyclqqfdcji5000010.jpg Edgar Link pending
gyclqqfdcji5000011.jpg Edgar Link pending
gyclqqfdcji5000012.jpg Edgar Link pending
gyclqqfdcji5000013.jpg Edgar Link pending
gyclqqfdcji5000014.jpg Edgar Link pending
gyclqqfdcji5000015.jpg Edgar Link pending
gyclqqfdcji5000016.jpg Edgar Link pending
gyclqqfdcji5000017.jpg Edgar Link pending
gyclqqfdcji5000018.jpg Edgar Link pending
gyclqqfdcji5000019.jpg Edgar Link pending
gyclqqfdcji5000020.jpg Edgar Link pending
gyclqqfdcji5000021.jpg Edgar Link pending
gyclqqfdcji5000022.jpg Edgar Link pending
gyclqqfdcji5000023.jpg Edgar Link pending
gyclqqfdcji5000024.jpg Edgar Link pending
gyclqqfdcji5000025.jpg Edgar Link pending
gyclqqfdcji5000026.jpg Edgar Link pending
gyclqqfdcji5000027.jpg Edgar Link pending
gyclqqfdcji5000028.jpg Edgar Link pending
gyclqqfdcji5000029.jpg Edgar Link pending
gyclqqfdcji5000030.jpg Edgar Link pending
gyclqqfdcji5000031.jpg Edgar Link pending
gyclqqfdcji5000032.jpg Edgar Link pending
gyclqqfdcji5000033.jpg Edgar Link pending
gyclqqfdcji5000034.jpg Edgar Link pending
gyclqqfdcji5000035.jpg Edgar Link pending
gyclqqfdcji5000036.jpg Edgar Link pending
gz2zbip3x3ju000001.jpg Edgar Link pending
gz2zbip3x3ju000002.jpg Edgar Link pending
gz2zbip3x3ju000003.jpg Edgar Link pending
gz2zbip3x3ju000004.jpg Edgar Link pending
gz2zbip3x3ju000005.jpg Edgar Link pending
gz2zbip3x3ju000006.jpg Edgar Link pending
gz2zbip3x3ju000007.jpg Edgar Link pending
gz2zbip3x3ju000008.jpg Edgar Link pending
gz2zbip3x3ju000009.jpg Edgar Link pending
gz2zbip3x3ju000010.jpg Edgar Link pending
gz2zbip3x3ju000011.jpg Edgar Link pending
gz2zbip3x3ju000012.jpg Edgar Link pending
gz2zbip3x3ju000013.jpg Edgar Link pending
gz2zbip3x3ju000014.jpg Edgar Link pending
gz2zbip3x3ju000015.jpg Edgar Link pending
gz2zbip3x3ju000016.jpg Edgar Link pending
gz2zbip3x3ju000017.jpg Edgar Link pending
gz2zbip3x3ju000018.jpg Edgar Link pending
gz2zbip3x3ju000019.jpg Edgar Link pending
gz2zbip3x3ju000020.jpg Edgar Link pending
gz2zbip3x3ju000021.jpg Edgar Link pending
gz2zbip3x3ju000022.jpg Edgar Link pending
gz2zbip3x3ju000023.jpg Edgar Link pending
gz2zbip3x3ju000024.jpg Edgar Link pending
gz2zbip3x3ju000025.jpg Edgar Link pending
gz2zbip3x3ju000026.jpg Edgar Link pending
gz2zbip3x3ju000027.jpg Edgar Link pending
gz2zbip3x3ju000028.jpg Edgar Link pending
gz2zbip3x3ju000029.jpg Edgar Link pending
gz2zbip3x3ju000030.jpg Edgar Link pending
gz2zbip3x3ju000031.jpg Edgar Link pending
gz2zbip3x3ju000032.jpg Edgar Link pending
gz2zbip3x3ju000033.jpg Edgar Link pending
gz2zbip3x3ju000034.jpg Edgar Link pending
gz2zbip3x3ju000035.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ttoo-10k_20181231.htm Edgar Link pending
ttoo-20181231.xml Edgar Link completed
ttoo-20181231.xsd Edgar Link pending
ttoo-20181231_cal.xml Edgar Link unprocessable
ttoo-20181231_def.xml Edgar Link unprocessable
ttoo-20181231_lab.xml Edgar Link unprocessable
ttoo-20181231_pre.xml Edgar Link unprocessable
ttoo-ex103_836.htm Edgar Link pending
ttoo-ex1041_1551.htm Edgar Link pending
ttoo-ex1045_829.htm Edgar Link pending
ttoo-ex1046_828.htm Edgar Link pending
ttoo-ex1047_827.htm Edgar Link pending
ttoo-ex1048_826.htm Edgar Link pending
ttoo-ex1049_825.htm Edgar Link pending
ttoo-ex1050_835.htm Edgar Link pending
ttoo-ex1051_834.htm Edgar Link pending
ttoo-ex1052_832.htm Edgar Link pending
ttoo-ex1053_833.htm Edgar Link pending
ttoo-ex1054_831.htm Edgar Link pending
ttoo-ex1055_830.htm Edgar Link pending
ttoo-ex211_18.htm Edgar Link pending
ttoo-ex231_6.htm Edgar Link pending
ttoo-ex232_823.htm Edgar Link pending
ttoo-ex311_14.htm Edgar Link pending
ttoo-ex312_24.htm Edgar Link pending
ttoo-ex321_8.htm Edgar Link pending
ttoo-ex322_824.htm Edgar Link pending